Terry,
You could be right, but I have a feeling the secondary offering will send it back a little bit first to even out any anticipated earnings per share dilution. After that, anything
can happen, and hopefully it's as you and Jim said. I understand the big growth push, but I do question why the need now given the "cash-rich" description of the company.
A secondary offering was more of what DANB potential investors were nervous about. Oh , well. For the long haul not likely to be a major issue, as RAIN should grow nicely.
Hoping your thoughts on DANB are accurate, as the earnings are due over the next week if memory serves me.
Not sure when Dennis is due back, but the thread isn't the same without him. I think he owes each of us a couple of shares.
Did you ever check out SBAM at all. If so, what did you think? From a biotech vantage point, I see the risk being lower and the potential gains being very good with ATIS, as
I've mentioned before. If you have any interest in the industry, I'd be interested in your opinion. I hear your rates have dropped, so why not ask?!
Regards,
Marshall |
